CD274 and glioblastoma: In glioblastoma, PD-1/PD-L1 immunotherapy has been explored in various studies; however, the unique immunosuppressive environment in the brain and the presence of the blood–brain barrier as well as the large intratumoral heterogeneity have limited its efficacy considerably.